| HOME >> BIOLOGY >> TECHNOLOGY |
About Diamyd Medical
Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company has currently three clinical-phase products.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's website: http://www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements. <start table>
For additional information, please contact:
Elisabeth Lindner,
President and CEO Diamyd Medical AB (publ.),
Tel: +46(0)8-661-00-26.
For pictures and press material, please contact:
Alexandra Fleetwood,
Director Communications Diamyd Medical AB (publ.),
alexandra.fleetwood@diamyd.com,
Tel: +46(0)8-661-00-26. <end table>
| SOURCE Diamyd Medical AB (publ) Copyright©2009 PR Newswire. All rights reserved |